Quest Diagnostics (Quest Diagnostics) Long-Term Capital Lease Obligation : $489 Mil (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Quest Diagnostics Long-Term Capital Lease Obligation?

Quest Diagnostics's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $489 Mil.

Quest Diagnostics's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 ($505 Mil) to Dec. 2023 ($503 Mil) and declined from Dec. 2023 ($503 Mil) to Mar. 2024 ($489 Mil).

Quest Diagnostics's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($494 Mil) to Dec. 2022 ($489 Mil) but then increased from Dec. 2022 ($489 Mil) to Dec. 2023 ($503 Mil).

Quest Diagnostics Long-Term Capital Lease Obligation Historical Data

The historical data trend for Quest Diagnostics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quest Diagnostics Long-Term Capital Lease Obligation Chart

Quest Diagnostics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

413.00

499.00

494.00

489.00

503.00

Quest Diagnostics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															490.00	508.00	505.00	503.00	489.00

Quest Diagnostics (NYSE:DGX) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Quest Diagnostics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Quest Diagnostics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Quest Diagnostics (Quest Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Quest Diagnostics Inc (NYSE:DGX) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

QDI:Germany

Address

500 Plaza Drive, Secaucus, NJ, USA, 07094

Website

https://www.questdiagnostics.com

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Executives

Luis Diaz	director	C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02138
Michael E Prevoznik	officer: Corp VP, Legal & Compliance	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Catherine T. Doherty	officer: SVP, Physician Services Bus.	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Timothy M Ring	director	C/O C.R BARD INC, 730 CENTRAL AVE, MURRAY HILL NJ 07974
Mark E Delaney	officer: SVP & Chief Commercial Officer	500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094
Mark A Gardner	officer: SVP of Molecular Gen & Oncol	500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094
Patrick Plewman	officer: SVP for Diagnostic Services	500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094
Karthik Kuppusamy	officer: SVP, Clinical Solutions	500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094
Michael J Deppe	officer: VP, Corp. Controller & CAO	500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS, SECAUCUS NJ 07094
Samer Abdul Samad	officer: Executive Vice President & CFO	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Stephen H Rusckowski	director, officer: President and CEO	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Tracey Doi	director	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Gail R Wilensky	director	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Mark Guinan	officer: Senior Vice President & CFO	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Daniel Stanzione	director	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094